Dyne Therapeutics
169 hedge funds and large institutions have $2.71B invested in Dyne Therapeutics in 2024 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 69 increasing their positions, 27 reducing their positions, and 16 closing their positions.
288% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 16
191% more capital invested
Capital invested by funds: $930M → $2.71B (+$1.78B)
156% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 27
150% more funds holding in top 10
Funds holding in top 10: 4 → 10 (+6)
36% more funds holding
Funds holding: 124 → 169 (+45)
2.49% more ownership
Funds ownership: 113.92% → 116.41% (+2.5%)
57% less call options, than puts
Call options by funds: $4.68M | Put options by funds: $10.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$112M |
| 2 |
RI
RTW Investments
New York
|
+$69.9M |
| 3 |
Janus Henderson Group
London,
|
+$60.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$57.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$52.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$42.2M |
| 2 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$37.7M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$33.9M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$28.6M |
| 5 |
Morgan Stanley
New York
|
-$24M |
DYN Hedge Fund Activity: Q1 2024 in Review
169 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2024, worth a combined $2.71B — up 191% from $930M a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new DYN positions and 16 closed out — a net gain of 46 holders — while 69 added to existing stakes and 27 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $112M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $42.2M.
- 169 institutional investors held Dyne Therapeutics (DYN) as of Q1 2024, up from 124 in Q4 2023.
- Funds reported $2.71B of Dyne Therapeutics stock for Q1 2024, up 191% quarter-over-quarter.
- 62 funds opened new Dyne Therapeutics positions in Q1 2024 and 16 closed out, a net change of +46 holders.
- The largest Dyne Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $112M added.
- The largest Dyne Therapeutics seller in Q1 2024 was Atlas Venture Life Science Advisors, an estimated $42.2M sold.
Based on aggregated 13F filings for Q1 2024.